Form 4: Johnson & Johnson Executive John C. Reed Reports Stock Transactions
SEC Form 4 Filing
EVP John C. Reed reports the vesting of restricted share units and subsequent tax withholding.
Summary
- On May 1, 2025, John C. Reed, EVP of Innovative Medicine R&D at Johnson & Johnson, reported transactions involving the company's common stock.
- 25,255 Restricted Share Units (RSUs) vested and converted into common stock.
- 11,002 shares were withheld for payment of taxes upon the vesting of the RSUs at a price of $156.31 per share.
- Following these transactions, Reed directly owns 29,795 shares of common stock.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing related to executive compensation, and does not inherently indicate positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of executive compensation and provide transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.
Key Dates
| Date | Description |
|---|---|
| 05/01/2023 | Date the Restricted Share Units (RSUs) were awarded under Issuer's Long-Term Incentive Plan. |
| 05/01/2025 | Date of RSU vesting and stock transactions. |
| 05/05/2025 | Date of signature on the Form 4 filing. |
Keywords
Form 4, JNJ, Johnson & Johnson, Executive Compensation, Stock Options, Restricted Stock Units, Beneficial Ownership, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.